We understand very well the unique and particular requirements that need to be met in Scotland so that an assessment can be made on the value of new medicines before these can be accepted for patient use.

A failure to either appreciate what’s important to payer decision making in Scotland or a lack of focus on those specific requirements of NHS Scotland, Healthcare Improvement Scotland and the Scottish Medicines Consortium will result in a less compelling application and consequently a less successful outcome.

At AXIS, we apply all our knowledge, insights and experience of working in the Scottish market and of the key stakeholders to optimise for a successful pricing and reimbursement outcome.

Submissions to the SMC

The purpose of the Scottish Medicines Consortium (SMC) is to assess the comparative clinical effectiveness and cost effectiveness of new medicines and accept those that clearly represent good value for money to NHS Scotland.

AXIS Consulting Scotland offers expert support to companies to develop highly customised and bespoke health technology assessment (HTA) submissions specifically for the SMC. We have extensive skills and knowledge in cost effectiveness modelling of outcomes relevant to the Scottish assessment bodies. We ensure accurate adaptation of global models for the local jurisdiction and apply local data in submissions.

From horizon scanning to gathering of Scottish clinician expert opinion to the development of a clear and compelling New Product Assessment Form application to attending the SMC meetings with you, we work hard at each and every stage to build a strong compelling value proposition that is clearly narrated to Scotland’s decision advisors and makers.

Evidence Generation

Regardless of which jurisdiction you are looking to make a pricing and reimbursement application, a high-quality evidence base is critical. There are times when additional evidence is required either de novo or gathered through a robust searching and review of the available literature. Our Scottish team has extensive experience in searching for data though carrying out comprehensive systematic or pragmatic literature reviews. We also conduct micro costing analysis to help inform the evidence base on cost of illness or care pathways.

To gather critically important clinician insights for our work in Scotland, we conduct in-depth face to face or virtual interviews while also hosting live or virtual Advisory Boards as well as Delphi Panels.

Pricing Supports for Scotland

We know that beyond the assessment on value conducted by the SMC, there is a need to put forward a compelling commercial offer to Scotland’s Patient Access Scheme Advisory Group (PASAG) which operates separately to the SMC and provides advice to NHS Scotland.

With over 22 years’ experience of developing pricing strategy for markets and of directly negotiating with payers in other similar markets such as Ireland, AXIS is very well placed to help you construct a compelling offer either as a simple discount or more complex outcomes-based scheme.